Penumbra – Consensus Indicates Potential 14.8% Upside

Broker Ratings

Penumbra with ticker code (PEN) have now 10 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The target price ranges between 235 and 167 with the average target price sitting at 202. Now with the previous closing price of 176 this would indicate that there is a potential upside of 14.8%. The 50 day moving average now sits at 182.32 while the 200 day moving average is 174.6. The market cap for the company is $7,250m. Find out more information at: https://www.penumbrainc.com

The potential market cap would be $8,321m based on the market concensus.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Penumbra designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra was incorporated in 2004 and is headquartered in Alameda, California.

Find more news, interviews, share price & company profile here for:

Good news travels fast (but only if you make that happen). Share on:

Twitter
LinkedIn
Facebook
Email
Reddit

AIM All Share Index